TELO Telomir Pharmaceuticals Corp: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

Telomir Pharmaceuticals (TELO) is accelerating the development of small molecules to stimulate telomerase in an effort to reverse inflammatory processes. The business leverages the global anti-aging market, focusing on therapies for anemia and pulmonary fibrosis. Price action based on the EV/EBITDA metric, which currently stands at 0.00, underscores the valuation's dependence on the success of clinical trials and the stability of long-term capital within the life-extension sector.

This fundamental indicator compares the total enterprise value to its operating profit before taxes and amortization, allowing for an assessment of business efficiency while accounting for the debt load. By analyzing the EV/EBITDA ratio in conjunction with the capital structure, an investor can discern the real value of assets at Telomir Pharmaceuticals (TELO), where the automation of drug synthesis is expected to offset the high costs of multi-year clinical trials conducted under scientific supervision.